Acimtamig

DB18674InvestigationalProtein Based Therapies

Acimtamig is a tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct.

Mechanism: Pharmacologically active on Low affinity immunoglobulin gamma Fc region receptor III-A and Tumor necrosis factor receptor superfamily member 8
Curator reviewed
Also known as: AFM13 (ANTI CD30 X ANTI CD16) · ANTI-CD30/CD16A MONOCLONAL ANTIBODY AFM13 · Immunoglobulin, anti-(human FcγRIIIa receptor) (human heavy chain V-D-J region) fusion protein with peptide linker (GGS)3 fusion protein with immunoglobulin anti-(human CD30 antigen) (human-Mus musculus single-chain Fv fragment VL-(GGS)3-VH) fusion prot · tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct
Code names: AFM13

Resolves to

Compound

Targets

What you can answer from here — as of September 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Acimtamig, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.